Firsocostat

Firsocostat
Names
	IUPAC name 2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid
Identifiers
CAS Number	1434635-54-7;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL3407547;
ChemSpider	58789974;
DrugBank	DB16166;
IUPHAR/BPS	10645;
KEGG	D11640;
PubChem CID	71528744;
UNII	XE10NJQ95M;
	InChI InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1 Key: ZZWWXIBKLBMSCS-FQEVSTJZSA-N;
	SMILES CC1=C(SC2=C1C(=O)N(C(=O)N2C[C@@H](C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5;
Properties
Chemical formula	C28H31N3O8S
Molar mass	569.63 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.^[1] It was discovered by Nimbus Therapeutics.^[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.^[3]

References